REGENXBIO Analysis: $358M Raised

Develop gene therapies for retinal diseases like wet AMD; Create treatments for Duchenne muscular dystrophy; Address MPS II (Hunter Syndrome) with gene therapy; Utilize over 100 novel AAV vectors in clinical programs; Manufacture gene therapy products in-house

REGENXBIO is primarily focused on developing gene therapy product candidates in the following therapeutic areas: retinal diseases, metabolic disorders, and neurodegenerative conditions. Their mission is to leverage the curative potential of gene therapy to improve lives.

REGENXBIO has developed several key innovations and products in the biotech sector, particularly in gene therapy for serious health conditions. Notable products include:

1. ABBV-RGX-314: A gene therapy candidate for treating wet age-related macular degeneration (AMD) and diabetic retinopathy, utilizing the NAV® AAV8 vector to deliver a gene encoding a monoclonal anti-VEGF antibody fragment. It is currently in pivotal and Phase II stages of development.

2. RGX-202: Designed for the treatment of Duchenne muscular dystrophy, RGX-202 employs the NAV® AAV8 vector to deliver a transgene for a novel microdystrophin. This product is in the pivotal stage.

3. RGX-121: Aimed at treating MPS II (Hunter Syndrome), RGX-121 uses the NAV® AAV9 vector to deliver the human iduronate-2-sulfatase gene to the central nervous system. It is also in the pivotal stage, with a Biologics License Application (BLA) filing expected in 2024.

These innovations reflect REGENXBIO's commitment to advancing gene therapy solutions.

REGENXBIO is primarily focused on developing gene therapy product candidates in the following therapeutic areas: retinal diseases, metabolic disorders, and neurodegenerative conditions. Their mission is to leverage the curative potential of gene therapy to improve lives.

REGENXBIO has received several recognitions in the biotech field, including being awarded the Washington Post's Top Workplaces in 2021, 2022, and 2023. Additionally, they received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for their RGX-121 gene therapy for Hunter syndrome.

REGENXBIO recently secured a strategic partnership with Nippon Shinyaku, which was announced in March 2025. This partnership includes an upfront payment of $110 million and potential milestone payments totaling up to $700 million, bringing the total value of the partnership to $810 million.

REGENXBIO has received several regulatory approvals and designations for its products and technologies, including:

1. RGX-121: A Biologics Licensing Application (BLA) has been submitted for RGX-121, which is on track for potential FDA approval in the second half of 2025. The company has also had a successful pre-BLA meeting with the FDA to support an accelerated approval pathway for this treatment.
2. RGX-202: This gene therapy has received Fast Track designation from the FDA, which facilitates the development and expedites the review of drugs that treat serious conditions and fill an unmet medical need.
3. RGX-111: The FDA granted Rare Pediatric Disease Designation to RGX-111, an investigational gene therapy product.

These approvals and designations highlight REGENXBIO's commitment to advancing gene therapies for various conditions.

REGENXBIO has established several significant partnerships in the biotech industry, including:

1. Nippon Shinyaku: REGENXBIO entered a strategic partnership with Nippon Shinyaku to develop and commercialize gene therapies RGX-121 and RGX-111 for MPS diseases. This partnership includes an upfront payment of $110 million and aims to advance treatments for rare diseases, with a focus on FDA approval by 2025.

2. AbbVie: REGENXBIO collaborates with AbbVie on the development of RGX-314, a gene therapy for retinal diseases such as wet AMD and diabetic retinopathy. This partnership involves shared costs for additional clinical trials.

3. Biogen: REGENXBIO has granted Biogen an exclusive worldwide research license for its NAV AAV8 and AAV9 vectors, which are used in the development of gene therapies.

4. Neurimmune: REGENXBIO partnered with Neurimmune to develop novel vectorized human antibodies for chronic neurodegenerative diseases.

These collaborations highlight REGENXBIO's commitment to advancing gene therapy treatments through strategic partnerships.

Awarded Washington Post's Top Work Places in 2021, 2022 & 2023; Developed partnerships with various organizations in gene therapy; Engaged in robust clinical programs across multiple therapeutic areas

REGENXBIO has received several recognitions in the biotech field, including being awarded the Washington Post's Top Workplaces in 2021, 2022, and 2023. Additionally, they received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for their RGX-121 gene therapy for Hunter syndrome.

REGENXBIO has established several significant partnerships in the biotech industry, including:

1. Nippon Shinyaku: REGENXBIO entered a strategic partnership with Nippon Shinyaku to develop and commercialize gene therapies RGX-121 and RGX-111 for MPS diseases. This partnership includes an upfront payment of $110 million and aims to advance treatments for rare diseases, with a focus on FDA approval by 2025.

2. AbbVie: REGENXBIO collaborates with AbbVie on the development of RGX-314, a gene therapy for retinal diseases such as wet AMD and diabetic retinopathy. This partnership involves shared costs for additional clinical trials.

3. Biogen: REGENXBIO has granted Biogen an exclusive worldwide research license for its NAV AAV8 and AAV9 vectors, which are used in the development of gene therapies.

4. Neurimmune: REGENXBIO partnered with Neurimmune to develop novel vectorized human antibodies for chronic neurodegenerative diseases.

These collaborations highlight REGENXBIO's commitment to advancing gene therapy treatments through strategic partnerships.